{"id":792690,"date":"2024-12-05T08:03:32","date_gmt":"2024-12-05T13:03:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/"},"modified":"2024-12-05T08:03:32","modified_gmt":"2024-12-05T13:03:32","slug":"veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/","title":{"rendered":"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Veterans\u2019 Research Foundation Spotlights CyPath<sup>\u00ae<\/sup> Lung\u2019s Addition to the Federal Supply Schedule<\/b><\/p>\n<p>SAN ANTONIO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<b>bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), <\/b>a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System (FSS) officials today in a joint presentation highlighting the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.va.gov%2Fhealth%2F&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=Veterans+Health+Administration&amp;index=1&amp;md5=5e3f91113d5323c4ada07e7e4ee5392a\">Veterans Health Administration<\/a> (VHA) award adding <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cypathlung.com&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=2&amp;md5=41c7d57d8f2823609f84a20bb38eba61\">CyPath<sup>\u00ae<\/sup> Lung<\/a> to the FSS procurement system for the VA\u2019s 1,380 healthcare facilities at a meeting of the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnavref.org%2F&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=National+Association+of+Veterans%26%238217%3B+Research+and+Education+Foundations&amp;index=3&amp;md5=8b640d5fc5b3e2efee60cb7972ee5df0\">National Association of Veterans\u2019 Research and Education Foundations<\/a> (NAVREF).<\/p>\n<p>\nThe VHA, part of the U.S. Department of Veterans Affairs (VA), serves 9.1 million veterans each year and is the largest integrated healthcare system in the country. CyPath<sup>\u00ae<\/sup> Lung is available to healthcare providers through the FSS that is utilized by the VHA and the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.health.mil%2F&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=Military+Health+System&amp;index=4&amp;md5=09efbcd038d24cbabe47eaf442c1983d\">Military Health System<\/a> to streamline access to state-of-the-art healthcare products and services.<\/p>\n<p>\n\u201cThe ability to sell CyPath<sup>\u00ae<\/sup> Lung to VA healthcare facilities, which include more than 170 medical centers and more than 1,000 outpatient sites across the country, opens a significant opportunity,\u201d bioAffinity President and CEO Maria Zannes said. \u201cWe appreciate that NAVREF recognized the importance of sharing information about CyPath<sup>\u00ae<\/sup> Lung with our VA colleagues and helping the Foundations\u2019 industry partners \u2013 including large pharmaceutical companies, biotech firms and medical partners \u2013 learn more about the invaluable assistance we received from the VA\u2019s National Acquisition Center professional staff.\u201d<\/p>\n<p>\n&#8220;NAVREF is proud to support innovative collaborations like the one between bioAffinity Technologies and the Veterans Health Administration,\u201d NAVREF Chief Executive Officer Rashi Romanoff said. \u201cThe inclusion of CyPath<sup>\u00ae<\/sup> Lung in the Federal Supply Schedule emphasizes the power of public-private partnerships to bring cutting-edge diagnostic tools to the VA, with the goal of improving health outcomes for veterans. We commend bioAffinity and the VA for their dedication to advancing lung cancer detection and care.&#8221;<\/p>\n<p>\nNAVREF is a nonprofit membership organization dedicated to advancing the vital work of research and education conducted by VA-affiliated nonprofits throughout the VA system. NAVREF provides resources, expertise, and advocacy to support its members in their mission to improve the lives of veterans through innovative research and educational initiatives. NAVREF has collaborated with the VA to streamline clinical trial opportunities for veterans, deliver cutting-edge care, and enhance education for VA healthcare staff, veterans, and their families. By prioritizing health innovation, NAVREF ensures that veterans benefit from groundbreaking research and accessible clinical trials across the nation. bioAffinity Technologies is a member of NAVREF\u2019s Industry Partner Consortium.<\/p>\n<p>\nVeterans are at higher risk for lung cancer due to older age, smoking and environmental exposure during and after military service. Through programs like the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.va.gov%2Fmiami-health-care%2Fprograms%2Flung-precision-oncology-program-lpop%2F&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=Lung+Precision+Oncology+Program&amp;index=5&amp;md5=cc6d8c46378c3549a2b834947786cb1b\">Lung Precision Oncology Program<\/a> (LPOP), the VA promotes annual lung cancer screening for high-risk individuals. CyPath<sup>\u00ae<\/sup> Lung is especially effective for patients who receive a positive screening result. When a low dose computed tomography (LDCT) scan reveals indeterminate pulmonary nodules, CyPath<sup>\u00ae<\/sup> Lung helps close the gap between a \u201cwait and see\u201d option and an invasive procedure, including biopsy, that may turn out to be unnecessary.<\/p>\n<p><b>About CyPath<sup>\u00ae<\/sup> Lung<\/b><\/p>\n<p>\nCyPath<sup>\u00ae<\/sup> Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath<sup>\u00ae<\/sup> Lung incorporates a fluorescent porphyrin, meso-tetra (4-carboxyphenyl) porphyrin (TCPP), that is preferentially taken up by cancer and cancer-related cells. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Frespiratory-research.biomedcentral.com%2Farticles%2F10.1186%2Fs12931-023-02327-3&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=Clinical+study+results&amp;index=6&amp;md5=9deab5fee4c0382bbbba8e9fffb00321\">Clinical study results<\/a> demonstrated that CyPath<sup>\u00ae<\/sup> Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cypathlung.com&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=www.cypathlung.com&amp;index=7&amp;md5=7f97b15ba7dec26fd41800ba3f945cb4\">www.cypathlung.com<\/a>.<\/p>\n<p><b>About bioAffinity Technologies, Inc.<\/b><\/p>\n<p>\nbioAffinity Technologies, Inc. (Nasdaq: BIAF) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company\u2019s first product, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcypath.precisionpath.us%2Fcypath-patient%2F&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=8&amp;md5=7bdfd34a6007a38b72e3abd3a7b65ef3\">CyPath<sup>\u00ae<\/sup> Lung<\/a>, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath\u00ae Lung is marketed as a Laboratory Developed Test (LDT) by <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.precisionpath.us%2F&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=Precision+Pathology+Laboratory+Services&amp;index=9&amp;md5=78edcc86465b683a4a101d21975ec740\">Precision Pathology Laboratory Services<\/a>, a subsidiary of bioAffinity Technologies. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=www.bioaffinitytech.com&amp;index=10&amp;md5=4e01ef8febb01a63dd0a2c8ab6e96ee3\">www.bioaffinitytech.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbioaffinitytechnologies%2F%3FviewAsMember%3Dtrue&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=11&amp;md5=29bae087671ee45a1cef6f621f80207e\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fbioaffinitytechnologies&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=Facebook&amp;index=12&amp;md5=64a05345ea1654e77811ca8bf9f4312a\">Facebook<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FbioAffinity&amp;esheet=54162259&amp;newsitemid=20241205274108&amp;lan=en-US&amp;anchor=X&amp;index=13&amp;md5=72a89ef1e89f38e5829b832ff498d635\">X<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nCertain statements in this press release constitute &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws. Words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;intend&#8221; or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the ability to sell CyPath\u00ae Lung to more than 170 medical centers and more than 1,000 outpatient sites across the country and access to VA medical facilities opening a significant opportunity. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to increase sales due to its access to VA medical facilities and the other factors discussed in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205274108r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20241205274108\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20241205274108\/en\/<\/a><\/span><\/p>\n<p><b>bioAffinity Technologies<br \/>\n<\/b><br \/>Julie Anne Overton<br \/>\n<br \/>Director of Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jao@bioaffinitytech.com\">jao@bioaffinitytech.com<\/a><\/p>\n<p><b>Investor Relations<br \/>\n<\/b><br \/>Dave Gentry<br \/>\n<br \/>RedChip Companies Inc.<br \/>\n<br \/>1-800-RED-CHIP (733-2447) or 407-491-4498<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:BIAF@redchip.com\">BIAF@redchip.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Texas<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Surgery Managed Care Medical Devices General Health Science Genetics Medical Supplies Clinical Trials Biotechnology Veterans Health Research Other Health Defense Radiology Pharmaceutical Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20241205274108\/en\/797432\/3\/bioAfinity_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System (FSS) officials today in a joint presentation highlighting the Veterans Health Administration (VHA) award adding CyPath\u00ae Lung to the FSS procurement system for the VA\u2019s 1,380 healthcare facilities at a meeting of the National Association of Veterans\u2019 Research and Education Foundations (NAVREF). The VHA, part of the U.S. Department of Veterans Affairs (VA), serves 9.1 million veterans each year and is the largest integrated healthcare system in the country. CyPath\u00ae Lung is available to healthcare providers through the FSS &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-792690","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System (FSS) officials today in a joint presentation highlighting the Veterans Health Administration (VHA) award adding CyPath\u00ae Lung to the FSS procurement system for the VA\u2019s 1,380 healthcare facilities at a meeting of the National Association of Veterans\u2019 Research and Education Foundations (NAVREF). The VHA, part of the U.S. Department of Veterans Affairs (VA), serves 9.1 million veterans each year and is the largest integrated healthcare system in the country. CyPath\u00ae Lung is available to healthcare providers through the FSS &hellip; Continue reading &quot;Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-05T13:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205274108r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule\",\"datePublished\":\"2024-12-05T13:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/\"},\"wordCount\":1079,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241205274108r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/\",\"name\":\"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241205274108r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2024-12-05T13:03:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241205274108r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241205274108r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/","og_locale":"en_US","og_type":"article","og_title":"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule - Market Newsdesk","og_description":"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule SAN ANTONIO&#8211;(BUSINESS WIRE)&#8211;bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System (FSS) officials today in a joint presentation highlighting the Veterans Health Administration (VHA) award adding CyPath\u00ae Lung to the FSS procurement system for the VA\u2019s 1,380 healthcare facilities at a meeting of the National Association of Veterans\u2019 Research and Education Foundations (NAVREF). The VHA, part of the U.S. Department of Veterans Affairs (VA), serves 9.1 million veterans each year and is the largest integrated healthcare system in the country. CyPath\u00ae Lung is available to healthcare providers through the FSS &hellip; Continue reading \"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-05T13:03:32+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205274108r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule","datePublished":"2024-12-05T13:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/"},"wordCount":1079,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205274108r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/","name":"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205274108r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2024-12-05T13:03:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205274108r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205274108r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veterans-research-foundation-spotlights-cypath-lungs-addition-to-the-federal-supply-schedule\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Veterans\u2019 Research Foundation Spotlights CyPath\u00ae Lung\u2019s Addition to the Federal Supply Schedule"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/792690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=792690"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/792690\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=792690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=792690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=792690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}